Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 13, Issue 6, Pages 535-551Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1744666X.2017.1295850
Keywords
Cytokine; interleukin-6; tocilizumab; rheumatoid arthritis; inflammation; pathogenesis
Categories
Ask authors/readers for more resources
Introduction: Rheumatoid arthritis (RA) is an autoimmune chronic disease with joint and systemic inflammation and it has been found that interleukin-6 (IL-6) plays a key role in RA. Indeed, various clinical studies have proved that the first-in-class IL-6 inhibitor, tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody, showed outstanding efficacy in RA.Areas covered: We review here the role of IL-6 in the inflammatory conditions and how IL-6 contributes to pathogenesis of RA, what induces IL-6 and how IL-6 expression is regulated. Furthermore, clinical studies of tocilizumab for RA are summarized,Expert commentary: We review and discuss the prospects for future applications of IL-6 targeting therapy and new therapeutic strategies targeting IL-6. Finally, we discuss relevant issues with regard to the clinical management of IL-6 blockade in RA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available